Table 4.
Medical treatment at inclusion and at 5 year follow-up (%).
| Women | Men | |||||||
|---|---|---|---|---|---|---|---|---|
| Inclusion | 5 Year Follow-Up | Inclusion | 5 Year Follow-Up | |||||
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
| No Prednisolone/DMARD | 19 | 8 | 30 | 14 | 13 | 9 | 28 | 18 |
| GC no DMARD | 15 | 3 | 6 | 4 | 19 | 5 | 7 | 3 |
| MTX* | 26 | 62 | 32 | 39 | 26 | 63 | 33 | 45 |
| SSZ* | 29 | 18 | 6 | 5 | 32 | 18 | 9 | 6 |
| Other mono* | 10 | 5 | 10 | 6 | 9 | 2 | 10 | 2 |
| Combination* | 1 | 3 | 10 | 9 | 1 | 2 | 7 | 11 |
| Biologics* | 0 | 1 | 6 | 23 | 0 | 1 | 6 | 15 |
*
With or without prednisolone, GC-Glucocorticoids
DMARD; disease modifying anti-rheumatic drug, GC; glucocorticoids, MTX; methotrexate, SSZ; sulphasalazine.